In short
A Phase 2 clinical trial is currently investigating MZE829, a promising new drug for adults with APOL1 Kidney Disease. This open-label study aims to evaluate how safe and effective MZE829 is for patients with proteinuric chronic kidney disease who have the APOL1 high-risk genotype. The trial is examining the drug's impact on albuminuria (protein in urine), a key indicator of kidney function, in two groups of patients: those with chronic kidney disease with concurrent diabetes and those without diabetes. MZE829 is administered as oral capsules, making it a potentially convenient treatment option if proven effective.
Key points
- MZE829 is currently being investigated in a Phase 2 clinical trial for adults with APOL1 Kidney Disease, a condition characterized by protein in the urine and progressive kidney damage. The 12-week study includes patients with and without diabetes and will evaluate whether the oral capsule medication is safe and can reduce albuminuria, an important marker of kidney function. Researchers will track adverse events and measure the percentage of participants achieving significant reductions in protein levels in their urine. The trial aims to determine if MZE829 could potentially become a new treatment option for this specific genetic form of kidney disease.
At a glance
- Study Type
- Phase 2, Open-Label Clinical Trial
- Drug Name
- MZE829
- Administration
- Oral capsules
- Target Condition
- APOL1 Kidney Disease (Proteinuric Chronic Kidney Disease with APOL1 High Risk Genotype)
- Study Participants
- Adults divided into two cohorts: ; 1. Chronic kidney disease with concurrent diabetes ; 2. Chronic kidney disease without concurrent diabetes
- Primary Outcome
- Safety and tolerability assessed by incidence of adverse events (Day 1 to Week 12)
- Key Secondary Outcomes
- 1. Percentage of participants with ≥30% reduction in UACR at Week 12 ; 2. Geometric mean plasma drug concentrations
- Study Duration
- 12 weeks
- Clinical Trial Identifier
- NCT06830629
What is MZE829?
MZE829 is an investigational medication currently being studied for the treatment of kidney disease associated with the APOL1 gene. It is administered as oral capsules and represents a potential breakthrough for patients with specific genetic kidney conditions. The drug is currently undergoing Phase 2 clinical trials to evaluate its safety and effectiveness.
What is APOL1 Kidney Disease?
APOL1 kidney disease is a condition that affects people who have certain high-risk variations of the APOL1 gene. This genetic kidney disease is characterized by proteinuria (protein in the urine), which indicates kidney damage. When proteins such as albumin leak into the urine (albuminuria), it's a sign that the kidneys' filtering function is compromised.
This condition can progress to chronic kidney disease (CKD), which means long-term kidney damage that can get worse over time. People with the APOL1 high-risk genetic variants are more susceptible to developing this type of kidney disease and may experience faster progression to kidney failure compared to those without these genetic variants.
Current Clinical Trial of MZE829
MZE829 is currently being studied in an open-label Phase 2 clinical trial. "Open-label" means that both the researchers and participants know which treatment is being administered. The primary purpose of this study is to evaluate the safety, tolerability, and effect of MZE829 on reducing albuminuria in adults with APOL1 kidney disease.
The trial focuses on participants who have both proteinuric chronic kidney disease (kidney disease with protein in the urine) and the APOL1 high-risk genotype (specific genetic variants that increase kidney disease risk).
How MZE829 Works
While the exact mechanism of action isn't fully detailed in the available information, MZE829 is designed to target the underlying problems associated with APOL1 kidney disease. The drug aims to reduce albuminuria, which is the presence of albumin protein in the urine and a key indicator of kidney damage.
By potentially reducing albuminuria, MZE829 may help slow the progression of kidney damage and preserve kidney function in people with the APOL1 high-risk genotype.
Who Can Benefit from MZE829?
The clinical trial for MZE829 includes two specific groups of participants:
- Cohort 1: People with chronic kidney disease who also have diabetes. Diabetes is a common cause of kidney disease, and these patients may have additional complications related to their diabetes.
- Cohort 2: People with chronic kidney disease who do not have diabetes. This helps researchers understand how the medication works in kidney disease that isn't complicated by diabetes.
All participants must have the APOL1 high-risk genotype and proteinuric kidney disease to be eligible for the study.
Expected Outcomes of MZE829 Treatment
The clinical trial is measuring several important outcomes to determine if MZE829 is effective and safe:
- Primary outcome: Safety and tolerability, assessed by monitoring for any side effects or adverse events from the start of treatment until week 12.
- Secondary outcomes:
- The percentage of participants who achieve at least a 30% reduction in UACR (Urinary Albumin-to-Creatinine Ratio) by week 12. UACR is a test that measures the amount of albumin in your urine compared to creatinine, providing an indication of kidney function.
- The geometric mean plasma drug concentrations, which shows how much of the drug is present in the bloodstream over time. This helps researchers understand how the body processes the medication.
The trial will follow participants for 12 weeks to assess these outcomes.
How MZE829 is Administered
MZE829 is provided as capsules for oral administration, which means participants can take the medication by mouth. This makes it relatively convenient compared to other treatments that might require injections or infusions. The specific dosing schedule and instructions would be provided to participants in the clinical trial.